Anti-p200 pemphigoid

Diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease

Conleth A. Egan, Carole Yee, Detlef Zillikens, Kim B. Yancey

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease. It is characterized by the binding of circulating IgG autoantibodies to the dermal side of 1 M NaCl split skin and by reactivity of these autoantibodies to a unique 200-kd antigen on immunoblot of dermal extract. On immunoelectron microscopic examination, these autoantibodies deposit at the lamina lucida-lamina densa interface. We describe the clinical, histologic, and immunopathologic features in a patient with anti-p200 pemphigoid, as well as his favorable response to treatment with systemic glucocorticosteroids and dapsone.

Original languageEnglish (US)
Pages (from-to)786-789
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume46
Issue number5
DOIs
StatePublished - May 1 2002

Fingerprint

Bullous Pemphigoid
Autoantibodies
Skin
Dapsone
Therapeutics
Immunoglobulin G
Antigens

ASJC Scopus subject areas

  • Dermatology

Cite this

Anti-p200 pemphigoid : Diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease. / Egan, Conleth A.; Yee, Carole; Zillikens, Detlef; Yancey, Kim B.

In: Journal of the American Academy of Dermatology, Vol. 46, No. 5, 01.05.2002, p. 786-789.

Research output: Contribution to journalArticle

@article{10f6a0056bdd420aa667e6a9a439a2f3,
title = "Anti-p200 pemphigoid: Diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease",
abstract = "Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease. It is characterized by the binding of circulating IgG autoantibodies to the dermal side of 1 M NaCl split skin and by reactivity of these autoantibodies to a unique 200-kd antigen on immunoblot of dermal extract. On immunoelectron microscopic examination, these autoantibodies deposit at the lamina lucida-lamina densa interface. We describe the clinical, histologic, and immunopathologic features in a patient with anti-p200 pemphigoid, as well as his favorable response to treatment with systemic glucocorticosteroids and dapsone.",
author = "Egan, {Conleth A.} and Carole Yee and Detlef Zillikens and Yancey, {Kim B.}",
year = "2002",
month = "5",
day = "1",
doi = "10.1067/mjd.2002.120923",
language = "English (US)",
volume = "46",
pages = "786--789",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Anti-p200 pemphigoid

T2 - Diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease

AU - Egan, Conleth A.

AU - Yee, Carole

AU - Zillikens, Detlef

AU - Yancey, Kim B.

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease. It is characterized by the binding of circulating IgG autoantibodies to the dermal side of 1 M NaCl split skin and by reactivity of these autoantibodies to a unique 200-kd antigen on immunoblot of dermal extract. On immunoelectron microscopic examination, these autoantibodies deposit at the lamina lucida-lamina densa interface. We describe the clinical, histologic, and immunopathologic features in a patient with anti-p200 pemphigoid, as well as his favorable response to treatment with systemic glucocorticosteroids and dapsone.

AB - Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease. It is characterized by the binding of circulating IgG autoantibodies to the dermal side of 1 M NaCl split skin and by reactivity of these autoantibodies to a unique 200-kd antigen on immunoblot of dermal extract. On immunoelectron microscopic examination, these autoantibodies deposit at the lamina lucida-lamina densa interface. We describe the clinical, histologic, and immunopathologic features in a patient with anti-p200 pemphigoid, as well as his favorable response to treatment with systemic glucocorticosteroids and dapsone.

UR - http://www.scopus.com/inward/record.url?scp=0036587405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036587405&partnerID=8YFLogxK

U2 - 10.1067/mjd.2002.120923

DO - 10.1067/mjd.2002.120923

M3 - Article

VL - 46

SP - 786

EP - 789

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5

ER -